{
    "nctId": "NCT00324363",
    "officialTitle": "Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin",
    "inclusionCriteria": "* Treated with a stable dose of one of the following for at least 3 months prior to screening: \\* \\>=1000 mg/day immediate-release metformin; or metformin \\>=1000 mg/day and sulfonylurea; or sulfonylurea/metformin combination therapy.\n* HbA1c between 7.1% and 11.0%, inclusive.\n* Body Mass Index (BMI) \\>21 kg/m\\^2 and \\<35 kg/m\\^2.\n* Must have minimum age of 21 Years\n* Must have maximum age of 75 Years",
    "exclusionCriteria": "* Have participated in this study previously, or any other study using exenatide or GLP-1 analogs.\n* Have participated in an interventional, medical, surgical, or pharmaceutical study within 30 days of screening.\n* Have characteristics contraindicating metformin or sulfonylurea use.\n* Have been treated with exogenous insulin for more than 1 week within the 3 months prior to screening.\n* Have used drugs for weight loss within 1 month of screening."
}